Bind Therapeutics, Inc.

Bind Biosciences, Inc.

Pfizer Corporation

Mir Mukkaram Ali

Stephen E Zale

James I Wright

Greg Troiano

Jeff Hrkach

Young-Ho Song

Christina Van Geen Hoven

David Dewitt

Abhimanyu Sabnis

Michael Figa

Maria Figueiredo

Jason Auer

Tarikh Christopher Campbell

Luis Alvarez De Cienfuegos

Susan Low

Tina Van Geen Hoven

The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.

Cancer cell targeting using nanoparticles

The present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures. Other aspects of the invention include methods of making such nanoparticles.

Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers

The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles.

Drug loaded polymeric nanoparticles and methods of making and using same

The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 1 to about 20 weight percent of a mTOR inhibitor; and about 70 to about 99 weight percent biocompatible polymer.

Therapeutic polymeric nanoparticles with mTOR inhibitors and methods of making and using same

The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 1 to about 20 weight percent of a vinca alkaloid; and about 50 to about 99 weight percent biocompatible polymer.

Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same

The present disclosure is directed in part to a biocompatible nanoparticle composition comprising a plurality of non-colloidal long circulating nanoparticles, each comprising a &#x3b1;-hydroxy polyester-co-polyether and a therapeutic agent, wherein such disclosed compositions provide a therapeutic effect for at least 12 hours.

Long circulating nanoparticles for sustained release of therapeutic agents

This application provides nanoparticles and methods of making nanoparticles using pre-functionalized poly(ethylene glycol)(also referred to as PEG) as a macroinitiator for the synthesis of diblock copolymers. Ring opening polymerization yields the desired poly(ester)-poly (ethylene glycol)-targeting agent polymer that is used to impart targeting capability to therapeutic nanoparticles. This 'polymerization from' approach typically employs precursors of the targeting agent wherein the reactivity of functional groups of the targeting agent is masked using protecting groups. Also described is a 'coupling to' that utilized the poly(ethylene glycol)-targeting agent conjugate where the targeting agent remains in its native un-protected form. This method uses &#x201c;orthogonal&#x201d; chemistry that exhibit no cross reactivity towards functional groups typically found within targeting agents of interest.

Growing community of inventors

Woburn, MA, United States of America

Mir Mukkaram Ali